Stage 1: History of Subacute B-Symptoms, Anemia & Massive Splenomegaly (Timestamp: 2 Months Prior to Admission)
A 51-year-old woman (residing in Delhi NCR, homemaker, past history of treated follicular thyroid carcinoma S/P thyroidectomy & radioiodine, migraine, depression/anxiety) presents with a 2-month history of fatigue, night sweats, left-upper-quadrant fullness, early satiety, pedal edema, and exertional dyspnea.
HPI:
- 1 Month Ago (1st Admission): Examination revealed massive splenomegaly extending to the pelvic brim (30 cm x 10 cm on CT) and ascites. Transfused 2 units PRBCs. HIV negative.
- Day 5 of 1st Admission: Prolonged aPTT noted that failed to correct on 1:1 mixing study. Transfused 3 units FFP + 2 units PRBCs. Bone marrow biopsy performed.
- Current Readmission: Recurrent fever (38.6°C), night sweats, progressive fatigue, and worsening pedal edema requiring transfer.
Hello, Chief Resident here.
Key Findings:
A 51-year-old female from Delhi NCR presenting with subacute B-symptoms, severe anemia, ascites, massive splenomegaly (30 cm), and a prolonged aPTT failing to correct on 1:1 mixing study, indicating a circulating anticoagulant/inhibitor.
Differential Diagnoses & Reasoning:
1. Splenic Lymphoproliferative Disorder (e.g., SMZL/DLBCL) or Primary Myelofibrosis (45%): Primary suspect given massive splenomegaly, B-symptoms, ascites, and paraneoplastic autoimmune phenomena (circulating inhibitor).
2. Visceral Leishmaniasis / Kala-azar (35%): Endemic in India; classically presents with massive splenomegaly, persistent fever, cytopenias, and hypergammaglobulinemia causing coagulation study interference.
3. Disseminated Tuberculosis or HLH (15%): Infectious/inflammatory driver fitting prolonged fever, cytopenias, splenomegaly, and severe dysregulation.
4. Metastatic Follicular Thyroid Carcinoma (5%): Known history, though isolated massive splenic metastasis is extremely rare.
Recommended Prioritized Tests:
1. Bone Marrow Aspirate & Biopsy Results: Flow cytometry, IHC, cytogenetics, and smears for LD bodies.
2. rK39 Immunochromatographic Test / Leishmania PCR.
3. Lupus Anticoagulant Panel & Specific Factor Assays (Factor VIII/IX/XI) to characterize the inhibitor.
4. Ascitic Fluid Analysis: Cell count, SAAG, cytology, and GeneXpert MTB/Rif.
5. HLH Workup: Serum ferritin, triglycerides, and fibrinogen levels.
Hello Attending Consultant here
Critique: Solid prioritization of BM and rK39, but underweights inhibitor characterization and ignores tropical co-infections endemic to Delhi NCR. Mixing-study failure needs immediate LA/factor workup before attributing to hypergammaglobulinemia. Ascites SAAG/cytology is essential; HLH labs are premature without ferritin trigger threshold.
Top 3 DDx:
1. Visceral leishmaniasis (with secondary inhibitor)
2. Splenic marginal-zone lymphoma
3. Primary myelofibrosis / prefibrotic PMF
Specific points:
1. Expedite LA panel + FVIII/FIX assays + Bethesda titer.
2. Add Leishmania PCR on BM/aspirate, not just rK39.
3. Quantify JAK2/CALR/MPL and BCR-ABL on BM.
4. CT chest/abdomen for nodal disease + PET if lymphoma likely.
5. Repeat aPTT post-FFP to assess inhibitor kinetics.
6. TB QuantiFERON + ascitic GeneXpert.
7. Hold empiric steroids until infection excluded.
Hello, Expert Clinician here.
Best unifying diagnosis: Visceral leishmaniasis (kala-azar). Months of fever and night sweats, massive splenomegaly, anemia, hypoalbuminemic ascites/edema, and a lupus-type inhibitor (described with chronic VL) cohere elegantly
Stage 2: Physical Exam & Severe Coombs-Negative Hemolytic Anemia (Timestamp: Admission / Day 1)
Physical Exam: Anxious, febrile (38.3°C), HR 105 bpm, BP 110/68 mmHg, RR 18/min, SpO2 96% on room air. Mild scleral icterus. No peripheral lymphadenopathy. Abdomen: Soft, non-tender; massive firm non-tender splenomegaly extending below the pelvic brim. Legs: Bilateral pitting pedal edema.
Initial Laboratory Workup:
- CBC & Reticulocytes: WBC 4,600/µL (67% neutrophils, 24% lymphocytes, 6% monocytes), Hemoglobin 7.2 g/dL (Hct 21.4%, MCV 89 fL, nadir 5.7 g/dL), Platelets 156,000/µL. Reticulocytes 9.2% (marked reticulocytosis!). Smear: 3+ Anisocytosis, 1+ Polychromasia, occasional Schistocytes.
- Hemolysis & Paraprotein Biomarkers: Total Bilirubin 2.4 mg/dL (Direct 0.7 mg/dL = indirect hyperbilirubinemia), LDH 1,540 U/L, Haptoglobin undetectable (<6 mg/dL). AST 44 U/L, ALT 19 U/L. Direct Coombs test & cold agglutinins negative.
- Serum Protein Electrophoresis: IgM kappa monoclonal paraprotein (0.12 g/dL) with severe immunoparesis (IgG 268 mg/dL, IgA 7 mg/dL).
Hello, Chief Resident here.
Updated Key Findings:
Coexistence of massive splenomegaly, Coombs-negative severe hemolysis (reticulocytes 9.2%, LDH 1540 U/L, undetectable haptoglobin, schistocytes), an IgM kappa monoclonal paraprotein (0.12 g/dL) with profound immunoparesis, and a prolonged uncorrected aPTT.
Differential Diagnoses & Reasoning:
1. Splenic Lymphoproliferative Disorder (e.g., SMZL or WM/Lymphoplasmacytic Lymphoma) (50%): Explains the IgM paraprotein, immunoparesis, massive splenomegaly, B-symptoms, and secondary Coombs-negative/hypersplenic hemolysis.
2. Visceral Leishmaniasis (30%): Geographically highly relevant; classically causes massive splenomegaly, B-symptoms, secondary hemolysis, and reactive monoclonal/polyclonal gammopathies with autoantibodies.
3. Primary Myelofibrosis (15%): Presents with massive splenomegaly, B-symptoms, and extramedullary hematopoiesis with fragmented red cells.
4. Thrombotic Microangiopathy / Atypical AIHA (5%): Drug/paraneoplastic-induced microangiopathic hemolysis accounting for schistocytes and negative DCT.
Prioritized Next Tests:
1. Bone Marrow Aspirate/Biopsy: Histology, flow cytometry, MYD88 L265P mutation, and Leishmania PCR/smear.
2. Serum Free Light Chain (SFLC) Assay & peripheral blood flow cytometry.
3. ADAMTS13 Activity & peripheral smear re-evaluation for TMA.
4. rK39 Rapid Diagnostic Test / Leishmania PCR.
5. Lupus Anticoagulant & Factor VIII/IX Activity Assays.
Hello Attending Consultant here
Critique: Overweights WM/SMZL given tiny IgM (0.12 g/dL) insufficient for hyperviscosity or primary hemolysis; under-explores parasite-driven cold-agglutinin-negative hemolysis and inhibitor. ADAMTS13 premature without more schistocytes/thrombocytopenia. BM remains pivotal but must include explicit LD-body stains + MYD88 only if LPL still viable.
Top 3 DDx:
1. Visceral leishmaniasis (secondary IgM, inhibitor, hypersplenism)
2. Splenic marginal-zone lymphoma
3. Prefibrotic myelofibrosis with extramedullary hemolysis
Specific points:
1. Urgent BM: Giemsa for amastigotes, Leishmania PCR, flow, JAK2/CALR.
2. Quantify cold-agglutinin titer + thermal amplitude despite neg screen.
3. Full LA panel + specific factor assays/Bethesda.
4. rK39 + blood/BM Leishmania PCR in parallel.
5. SFLC ratio + urine immunofixation for clone significance.
6. Haptoglobin/LDH serials post-transfusion; avoid empiric steroids.
7. PET-CT only after infection excluded.
Hello, Expert Clinician here.
Best unifying diagnosis: Visceral leishmaniasis. It elegantly explains the massive splenomegaly, chronic B-symptoms, secondary hypersplenic hemolysis, polyclonal/monoclonal immune dysregulation with severe immunoparesis, and the lupus-like inhibitor causing the uncorrected aPTT. The schistocytes point to a microangiopathic component from severe hypersplenism rather than a primary TMA, especially given normal platelets.
Top differentials:
1. Splenic marginal-zone lymphoma — fits splenomegaly + IgM, but the tiny 0.12 g/dL paraprotein and profound hemolysis out of proportion argue against primary clone.
2. Primary myelofibrosis — massive spleen + B-symptoms, yet no teardrop cells/leukoerythroblastosis or marrow fibrosis clues yet.
3. Lymphoplasmacytic lymphoma/Waldenström — IgM + immunoparesis, but paraprotein too small and hemolysis atypically Coombs-negative.
4. Atypical TMA — schistocytes + hemolysis, but normal platelets and absence of renal dysfunction make it less likely.
Key pivot: The uncorrected aPTT (circulating inhibitor) + Coombs-negative hemolysis strongly shift the case from a pure clonal B-cell disorder toward an infectious/paraneoplastic mimic such as VL.
Most important next move: Immediate bone marrow Giemsa stain for Leishman-Donovan bodies plus Leishmania PCR, simultaneously with rK39 serology and lupus anticoagulant/factor assays. This single test can unify splenomegaly, hemolysis, paraprotein, and coagulopathy in an endemic region.
Teaching pearl: In a patient from a VL-endemic area presenting with massive splenomegaly, pancytopenia/hemolysis, monoclonal gammopathy, and acquired inhibitor, exclude kala-azar before labeling the process lymphoma—VL is the great hematologic masquerader.
Stage 3: Mixing Study, Lupus Anticoagulant & Abdominal CT Imaging (Timestamp: Hospital Days 1-2)
Coagulation Studies & Autoantibodies:
- PT 14.7s (INR 1.3), aPTT 63.9s (severely prolonged!). Fibrinogen 499 mg/dL, D-Dimer 2,101 ng/mL.
- Mixing Study: 1:1 mixing with normal plasma failed to correct the prolonged aPTT (persisted >60s).
- Autoantibody Panel: Lupus Anticoagulant POSITIVE; IgM Anticardiolipin Autoantibodies >150 MPL units (strongly positive!).
Contrast CT Imaging: Massive homogeneous splenomegaly (30 cm in length) extending into the pelvic brim, with enlarged lymph nodes in the splenic hilum and para-aortic region. No focal splenic lesions.
Hello, Chief Resident here.
Updated Key Findings:
Massive 30 cm homogeneous splenomegaly with hilar/para-aortic lymphadenopathy, severe Coombs-negative hemolysis, small IgM kappa paraprotein, and high-titer Antiphospholipid Antibodies (Lupus Anticoagulant positive, IgM Anticardiolipin >150 MPL) driving the uncorrected aPTT prolongation.
Differential Diagnoses & Reasoning:
1. Visceral Leishmaniasis with secondary Antiphospholipid Syndrome (55%): Endemic trigger in Delhi NCR capable of producing massive splenomegaly, reactive IgM paraproteinemia, severe Coombs-negative hemolysis, and secondary high-titer antiphospholipid antibodies.
2. Splenic Lymphoproliferative Disorder (e.g., SMZL or DLBCL) (30%): Homogeneous massive splenomegaly, lymphadenopathy, and IgM paraprotein with paraneoplastic autoantibody production.
3. Primary Myelofibrosis (10%): Explains massive splenomegaly, extramedullary disease, and secondary autoantibodies, though marked aCL titers are atypical.
4. Primary Antiphospholipid Syndrome / SLE (5%): Explains severe hemolysis and high-titer aCL/LA, but a 30 cm spleen is extremely rare.
Prioritized Next Steps:
1. Bone Marrow Aspirate & Biopsy: Giemsa stain for LD bodies, Leishmania PCR, flow cytometry, and JAK2/MYD88 mutation analysis.
2. rK39 Rapid Diagnostic Test & Peripheral Blood Leishmania PCR.
3. Factor Assays (VIII, IX, XI, XII): Exclude true factor deficiencies before invasive procedures.
4. Autoimmune Panel: ANA, anti-dsDNA, C3/C4 levels.
Hello Attending Consultant here
Critique: Appropriately elevates VL with secondary APS, but overcalls primary APS/SLE (spleen size incompatible) and under-emphasizes need for immediate factor assays before any procedure. BM plan solid; add explicit amastigote stains. ANA panel low-yield without other SLE features.
Top 3 DDx:
1. Visceral leishmaniasis (secondary APS + IgM clone)
2. Splenic marginal-zone lymphoma (paraneoplastic aPL)
3. Lymphoplasmacytic lymphoma / WM variant
Specific points:
1. Urgent BM Giemsa + Leishmania PCR/rK39.
2. Factor VIII/IX/XI assays + Bethesda before biopsy.
3. MYD88 L265P + BRAF on BM/flow.
4. Serial aPL titers; avoid anticoagulation absent thrombosis.
5. PET-CT for nodal FDG avidity post-infection exclusion.
6. Hold steroids/IVIG until VL ruled out.
7. Quantify cryoglobulins given IgM + aCL.
Hello, Expert Clinician here.
Best unifying diagnosis: Visceral leishmaniasis with secondary antiphospholipid antibodies and an IgM paraprotein. Endemic kala-azar explains the massive homogeneous splenomegaly, B-symptoms, hypersplenic Coombs-negative hemolysis, high-titer aCL/LA, and small reactive IgM clone.
Top differentials:
1. Splenic marginal-zone lymphoma – fits splenomegaly, nodes, IgM, and paraneoplastic aPL, but profound immunoparesis and hemolysis exceed the tiny paraprotein.
2. Primary myelofibrosis – massive spleen + hemolysis, yet lacks teardrop/leukoerythroblastosis and strongly positive aPL is unusual.
3. Primary APS/SLE – explains aPL + hemolysis, but a 30 cm spleen and IgM paraprotein are atypical.
Key pivot: Extremely high-titer antiphospholipid antibodies with an uncorrected mixing study strongly point to a secondary (infectious or lymphoproliferative) driver rather than primary APS.
Next move: Bone marrow Giemsa for Leishman-Donovan bodies + Leishmania PCR and rK39, performed only after confirming adequate factor VIII/IX/XI levels. Flow cytometry/MYD88 can run in parallel.
Teaching pearl: In endemic regions, visceral leishmaniasis frequently produces high-titer antiphospholipid antibodies, lupus anticoagulant, and monoclonal gammopathy—mimicking APS or lymphoma—so always exclude kala-azar before labeling the process autoimmune or malignant.
Stage 4: Bone Marrow Biopsy, Flow Cytometry & Pathologic Unification (Timestamp: Hospital Days 3-5)
Bone Marrow Histopathology & Flow Cytometry:
- Bone Marrow Histopathology: Nodular and intrasinusoidal aggregates of small B-lymphocytes comprising ~10% of marrow cellularity (excluding Hairy-Cell Leukemia, which shows diffuse interstitial infiltration).
- Flow Cytometry (Marrow & Blood): Clonal B-cell population expressing kappa light chain, CD19+, but CD5-, CD23-, CD10-, and CD103-. Smear: Occasional mildly enlarged lymphocytes with non-circumferential villous cytoplasmic projections ("villous lymphocytes").
- Unifying Diagnosis: Splenic Marginal-Zone Lymphoma (SMZL) presenting with massive splenomegaly, IgM kappa paraproteinemia, Coombs-negative autoimmune hemolytic anemia (driven by warm IgM autoantibodies / splenic sequestration), and secondary Antiphospholipid Syndrome (Lupus Anticoagulant).
Hello, Chief Resident here.
Updated Key Findings:
Bone marrow histopathology and flow cytometry establish intrasinusoidal CD19+ CD5- CD10- CD23- CD103- B-cell infiltration (~10%) with circulating villous lymphocytes, confirming Splenic Marginal-Zone Lymphoma (SMZL) complicated by secondary Antiphospholipid Syndrome (LA positive, high-titer aCL), IgM kappa paraproteinemia, and severe Coombs-negative hemolysis.
Differential Diagnoses & Reasoning:
1. Splenic Marginal-Zone Lymphoma (SMZL) with Secondary APS & AIHA (95%): Pathologically confirmed by characteristic intrasinusoidal infiltration, immunophenotype, villous lymphocytes, and massive splenomegaly.
2. Lymphoplasmacytic Lymphoma / Waldenström Variant (3%): Overlapping IgM secretion, but CD5-/CD10-/CD103- phenotype and intrasinusoidal pattern favor SMZL.
3. Visceral Leishmaniasis (Infectious Mimic) (2%): Effectively ruled out by definitive diagnostic histopathology.
Recommended Next Steps in Management:
1. Molecular & Cytogenetic Profiling: Test for NOTCH2, KLF2 mutations, and 7q deletion to assist risk stratification.
2. Hepatitis C Virus (HCV) Serology: Screen for HCV as a potentially reversible underlying driver of SMZL.
3. Serum Cryoglobulin Level: Evaluate for cryoglobulinemia secondary to the monoclonal IgM kappa paraprotein.
4. Initiate Target Therapy: Commencing Rituximab monotherapy (or chemoimmunotherapy) to treat the underlying B-cell clone and clear paraneoplastic autoantibodies.
5. Thromboprophylaxis Assessment: Monitor for thrombosis versus bleeding risk before initiating anticoagulation.
Hello Attending Consultant here
Critique: Path confirmation of SMZL is robust (intrasinusoidal CD5-/CD103- clone + villous lymphocytes), yet plan under-addresses concurrent infection exclusion and hemolysis kinetics before rituximab. HCV screen essential; empiric therapy premature without full staging/cryoglobulin data. APS thrombosis risk needs formal Caprini scoring.
Top 3 DDx:
1. SMZL (secondary APS + IgM-driven AIHA)
2. SMZL/LPL overlap (MYD88-neg variant)
3. HCV-associated SMZL
Specific points:
1. Add MYD88 L265P + NOTCH2/KLF2/del7q on BM.
2. Urgent HCV RNA + cryoglobulins + RF.
3. PET-CT for extranodal burden pre-therapy.
4. Serial hemolysis markers; consider brief steroids only if life-threatening.
5. Hold full anticoagulation; ASA if no bleed.
6. Rituximab monotherapy first-line; defer bendamustine.
7. Repeat aPL titers 12 weeks post-treatment.
Hello, Expert Clinician here.
Best unifying diagnosis: Splenic marginal-zone lymphoma (SMZL). Intrasinusoidal/nodular marrow infiltration, CD19+ CD5- CD10- CD23- CD103- immunophenotype, circulating villous lymphocytes, massive splenomegaly, IgM kappa paraprotein, Coombs-negative hemolysis, and secondary antiphospholipid antibodies unify the case.
Top differentials:
1. Lymphoplasmacytic lymphoma/WM – overlaps IgM, but intrasinusoidal pattern, villous morphology, and absent CD103 argue against it.
2. Hairy-cell leukemia variant – splenomegaly + cytopenias, yet CD103 negativity and nodular pattern exclude it.
3. Visceral leishmaniasis – strong mimic earlier, now definitively excluded by diagnostic marrow histology and flow.
Key pivot: Bone marrow biopsy showing classic SMZL histology turned the picture from an infectious/autoimmune mimic into a clonal B-cell disorder driving secondary APS and hemolysis.
Most important next move: Screen for HCV and cryoglobulins, add MYD88/NOTCH2/KLF2 testing, then initiate rituximab-based therapy after hemolysis stabilization and infection exclusion. Anticoagulation should await individualized thrombosis-bleeding assessment.
Teaching pearl: SMZL commonly masquerades as infection or primary autoimmune disease through paraproteinemia, autoimmune hemolysis, and antiphospholipid antibodies; intrasinusoidal marrow infiltration with villous lymphocytes is the diagnostic clue that should prompt early B-cell directed therapy rather than empiric steroids.
Stage 5: Therapeutic Splenectomy & Chemoimmunotherapy Outcome (Timestamp: Follow-up & Discharge)
Management & Surgical Intervention:
- Primary Treatment: Therapeutic & Diagnostic Splenectomy performed (spleen weighed 2.42 kg!). Pathological examination confirmed classic Splenic Marginal-Zone Lymphoma.
- Post-Operative Course: Complete resolution of fevers and night sweats; hemoglobin and hematocrit normalized within 6 weeks, and aPTT normalized.
- Relapse & Long-Term Outcome: At 15 Months: Recurrence of fatigue, anemia, IgM paraprotein, retroperitoneal lymphadenopathy, and DVT. Successfully treated with Rituximab + CVP (Cyclophosphamide, Vincristine, Prednisone) chemotherapy + LMWH anticoagulation, achieving complete hematologic and clinical response.
Hello, Chief Resident here.
Updated Key Findings:
Pathologically confirmed SMZL (2.42 kg spleen) with complete resolution of secondary APS/hemolysis post-splenectomy. Relapse at 15 months with retroperitoneal lymphadenopathy, IgM paraprotein, and DVT achieved complete response following Rituximab-CVP and LMWH.
Differential Diagnoses & Reasoning:
1. Relapsed SMZL, in Complete Remission post-R-CVP (95%): Classic pattern of extra-splenic nodal recurrence post-splenectomy, demonstrating complete clinical/hematologic response to chemoimmunotherapy.
2. Histologic Transformation to DLBCL (4%): Known risk during SMZL relapse; sustained response to R-CVP makes aggressive transformation less likely.
3. Resolved Secondary Antiphospholipid Syndrome (1%): Paraneoplastic autoantibody production fully suppressed following clearance of the underlying B-cell clone.
Prioritized Next Steps in Management:
1. Serial IgM & SPEP/SFLC Monitoring: Track clonal disease burden and screen for early biochemical relapse.
2. Surveillance CT Imaging (Abdomen/Pelvis): Assess nodal response duration and monitor retroperitoneal disease.
3. Repeat Antiphospholipid Panel (LA/aCL): Determine if autoantibodies cleared to guide the duration of long-term anticoagulation.
4. Post-Splenectomy Prophylaxis & Immunoglobulins: Maintain immunizations against encapsulated pathogens and monitor IgG levels post-Rituximab.
Hello Attending Consultant here
Critique: Surveillance plan appropriate post-R-CVP CR, but under-specifies aPL re-testing timing, anticoagulation duration (provoked DVT in active disease), and transformation vigilance. Ig monitoring good; add MRD if available. Post-splenectomy vaccines must be confirmed complete.
Top 3 DDx:
1. Relapsed SMZL now in CR (post-splenectomy + R-CVP)
2. SMZL with residual secondary APS risk
3. Occult histologic transformation (low probability given R-CVP response)
Specific points:
1. Repeat LA/aCL/β2GP1 at 12 weeks off therapy; stop LMWH if negative.
2. Confirm post-splenectomy vaccines (pneumo/mening/Hib) + boosters.
3. q3mo SPEP/SFLC + IgM for 2 yrs, then q6mo.
4. CT or PET at 6 mo to document nodal CR durability.
5. Watch for transformation (rising LDH, new B-symptoms → biopsy).
6. Pneumocystis prophylaxis if prolonged steroids/Ritux.
7. Thrombophilia panel only if unprovoked recurrence.
Hello, Expert Clinician here.
Best unifying diagnosis: Splenic marginal-zone lymphoma (SMZL) with secondary antiphospholipid syndrome and warm-type autoimmune hemolytic anemia. The massive spleen, villous lymphocytes, IgM kappa paraprotein, aPL positivity, dramatic response to splenectomy, and later extra-splenic relapse treated successfully with R-CVP confirm this unified picture.
Top differentials:
1. Lymphoplasmacytic lymphoma/WM – overlaps IgM, but intrasinusoidal marrow pattern and villous morphology favor SMZL.
2. Visceral leishmaniasis – early mimic now excluded by histology and sustained response to B-cell therapy.
3. Histologic transformation to DLBCL – less likely given complete response to R-CVP.
Key pivot: Bone marrow biopsy revealing classic SMZL turned an infectious/autoimmune mimic into a clonal B-cell disorder driving paraneoplastic APS and hemolysis.
Next move: Continue surveillance IgM/SPEP and imaging; repeat antiphospholipid panel after therapy to determine whether long-term anticoagulation remains necessary; ensure complete post-splenectomy vaccination and monitor for transformation.
Teaching pearl: SMZL often presents as a paraneoplastic autoimmune syndrome (AIHA + APS + paraprotein) and can initially masquerade as infection; splenectomy is diagnostic/therapeutic early, but relapse is typically nodal and responds well to rituximab-based chemoimmunotherapy.